4baseCare, an Illumina-backed company based in Singapore, is excited to announce a significant funding milestone, having raised $6 million in its latest funding round. This strategic infusion of capital comes at a pivotal time as the company accelerates its commitment to advancing Precision Oncology Solutions. Utilizing Advanced Genomics and innovative digital health technology, 4baseCare is at the forefront of developing customized cancer treatment options that address the unique clinical outcomes presented by diverse populations.
The recently secured funds will primarily be allocated towards enhancing our proprietary indigenous comprehensive cancer gene panels, designed to empower oncologists in selecting the most effective precision therapies for their patients. These groundbreaking genomic testing solutions utilize Next-Gen Sequencing (NGS) to evaluate tumour genomic alterations, enabling somatic mutation analysis via tissue or liquid biopsies. Furthermore, we offer germline mutation testing for hereditary and familial cancers through peripheral blood samples.
By expanding our genomic testing portfolio and enhancing our technological capabilities, 4baseCare aims to significantly personalize patient care in Oncology, ensuring that innovative treatments are tailored to the unique genetic profiles of individuals. As part of the Illumina Accelerator's 10th Cycle, we are poised to create impactful changes in the landscape of cancer care by leveraging cutting-edge science and technology. We are genuinely optimistic about the future and look forward to translating this funding into tangible health benefits for patients worldwide.
.png&w=3840&q=75)